Institution

University Hospital Heidelberg

Heidelberg, GermanyWebsite

Also known as: Heidelberg University Hospital · Universitaetsklinikum Heidelberg · University Hospital of Heidelberg · Universitätsklinikum Heidelberg

378running trials
137closed trials
62,017publications (OpenAlex)

Running trials

Not yet recruiting
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
NCT05662904· Phase 1· German Cancer Research Center· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
NCT07431294· Phase 1· Bayer· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
NCT07825064· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Not yet recruiting
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor
NCT07557147· Bayer· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
2024-519592-26-00· Phase 1· Universitaetsklinikum Heidelberg AöR· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Servier· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Not yet recruiting
Phase 2 Trial of TAK-755 for Acute Ischemic Stroke
2025-522734-31-00· Phase 2· Takeda Development Center Americas Inc.· Source
Recruiting
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163· Phase 2· Bicara Therapeutics· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242· Phase 3· Avidity Biosciences, Inc.· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· AstraZeneca· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00· Phase 3· Avidity Biosciences Inc.· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
NCT07553650· Charite University, Berlin, Germany· Source
Recruiting
The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?
2025-524443-12-00· Phase 2· Goethe University Frankfurt· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· Phase 3· Nektar Therapeutics· Source
Recruiting
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00· Phase 1/2· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
PREFer
NCT06916416· Phase 2· University Of Cologne· Source
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· Phase 3· AbbVie· Source
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450· Phase 2· Takeda· Source
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
NCT07221669· Phase 3· Biogen· Source
Active, not recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
2025-522440-41-00· Phase 2· Bluefin Biomedicine Inc.· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
NCT07585890· University Medical Center Groningen· Source
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source
Not yet recruiting
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
NCT07549607· University of Leipzig· Source
Recruiting
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial
2024-516544-26-00· Phase 2· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
Ambulatory Stroke Unit Treatment for Elderly Patients
NCT07420374· University Hospital Heidelberg· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
Mental Health and Suicidality in Glioblastoma Patients in Germany
NCT07409584· University Hospital, Essen· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source

Showing 50 of 378.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers31 recruiting
Stroke19 recruiting
Multiple myeloma16 recruiting
Melanoma13 recruiting
Heart failure12 recruiting
Acute myeloid leukaemia11 recruiting
Glioblastoma10 recruiting
Amyloidosis9 recruiting
Liver and biliary tract cancer9 recruiting
Pancreatic cancer9 recruiting
Sarcoma9 recruiting
Acute lymphoblastic leukaemia8 recruiting
Colorectal cancer7 recruiting
Lung cancer7 recruiting
Prostate cancer7 recruiting
Fatty liver disease (MASLD/MASH)6 recruiting
Bladder cancer5 recruiting
Chronic kidney disease5 recruiting
Follicular lymphoma5 recruiting
Head and neck cancer5 recruiting
Kidney cancer5 recruiting
Ovarian cancer5 recruiting
Atopic dermatitis (eczema)4 recruiting
Gastric and oesophageal cancer4 recruiting
High blood pressure4 recruiting
Liver cirrhosis4 recruiting
Metastatic breast cancer4 recruiting
Myeloproliferative neoplasms4 recruiting
Atrial fibrillation3 recruiting
Chronic lymphocytic leukaemia3 recruiting
Crohn's disease3 recruiting
Diffuse large B-cell lymphoma3 recruiting
Hodgkin lymphoma3 recruiting
Multiple sclerosis3 recruiting
Myelodysplastic syndromes3 recruiting
Rheumatoid arthritis3 recruiting
Brain aneurysm2 recruiting
Cervical cancer2 recruiting
Chronic myeloid leukaemia2 recruiting
Coronary artery disease2 recruiting
Duchenne muscular dystrophy2 recruiting
Endometrial cancer2 recruiting
Hypertrophic cardiomyopathy2 recruiting
IgA nephropathy2 recruiting
Lupus (SLE)2 recruiting
Macular degeneration2 recruiting
Mantle cell lymphoma2 recruiting
Meningioma2 recruiting
Neuroendocrine tumours2 recruiting
Obesity2 recruiting
Psoriasis2 recruiting
Pulmonary arterial hypertension2 recruiting
Sickle cell disease2 recruiting
Systemic sclerosis (scleroderma)2 recruiting
Alzheimer disease1 recruiting
ANCA-associated vasculitis1 recruiting
Hidradenitis suppurativa1 recruiting
Immune thrombocytopenia (ITP)1 recruiting
Long COVID and ME/CFS1 recruiting
Myocarditis1 recruiting
Osteoarthritis1 recruiting
Parkinson disease1 recruiting
Peripheral artery disease1 recruiting
Polycystic kidney disease1 recruiting
Pompe disease1 recruiting
Primary biliary cholangitis1 recruiting
Spinal muscular atrophy1 recruiting
Thyroid cancer1 recruiting
Triple-negative breast cancer1 recruiting
Tuberculosis1 recruiting
Ulcerative colitis1 recruiting
Vitiligo1 recruiting

Closed trials

Completed
A Study Evaluating BFB759 in Atopic Dermatitis
2025-521624-30-00· Phase 2· Bluefin Biomedicine Inc.· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887· Phase 1/2· Alexion Pharmaceuticals, Inc.· Source
Completed
Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure
NCT07181291· St. Josefs-Hospital Wiesbaden GmbH· Source
Completed
KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer
NCT05846516· Phase 1· Boehringer Ingelheim International GmbH· Source
Completed
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
2023-508998-85-00· Phase 1· Boehringer Ingelheim International GmbH· Source
Completed
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
NCT04524208· Phase 2· Universitaetsmedizin Goettingen· Source
Completed
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· Phase 3· Ipsen· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis
2023-504092-25-00· Phase 2· Enterprise Therapeutics Limited· Source
Completed
A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
2023-507207-66-00· Phase 3· Oculis Operations S.a.r.l.· Source
Recruiting
Sacituzumab Govitecan in Metastatic Colorectal Cancer
NCT06243393· Phase 2/3· University Hospital Heidelberg· Source
Completed
Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency.
2023-503256-27-00· Phase 1· MEDA Pharma GmbH & Co. KG· Source
Active, not recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158· Phase 3· University of Heidelberg Medical Center· Source
Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source
Completed
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source
Completed
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· Phase 3· Amgen· Source
Completed
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
2023-505558-16-00· Phase 3· Almirall S.A.· Source
Completed
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Celgene· Source
Completed
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
NCT04363801· Phase 2· Leap Therapeutics Inc.· Source
Completed
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
2022-502040-13-00· Phase 2· University of Leipzig· Source
Completed
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
2022-502787-20-00· Phase 2· IO Biotech ApS· Source
Active, not recruiting
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· Phase 3· Cytokinetics· Source
Completed
Clinical trial of MK-7648A in adults and children with skin cancer
NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
NCT05911009· Phase 2· Berlin Cures GmbH· Source
Completed
Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).
NCT06125808· Phase 2· Arctic Bioscience· Source
Active, not recruiting
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
NCT05833438· Phase 2· University of Leipzig· Source
Completed
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma
2022-501423-25-00· Phase 1/2· Curevac AG· Source
Completed
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy
NCT05582395· Phase 3· Myokardia Inc.· Source
Terminated
Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy
NCT05570409· Phase 2/3· LMU Klinikum· Source
Completed
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)
2022-501850-12-00· Phase 2· Arctic Bioscience AS· Source
Completed
Guiding Catheters in Endovascular Stroke Therapy - Are Balloon Guided Catheters Superior?
NCT07478042· University Hospital Heidelberg· Source
Completed
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
NCT05774431· University Hospital Heidelberg· Source
Completed
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)
NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source
Completed
A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)
2024-512451-20-00· Phase 2/3· Klinikum der Universitaet Muenchen AöR· Source
Completed
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Completed
Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma
NCT06321562· Phase 1· Eyed Pharma· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
NCT05619744· Phase 1· Hoffmann-La Roche· Source
Completed
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
NCT05184088· Phase 3· Lantheus Germany GmbH· Source
Completed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642· Phase 3· Hoffmann-La Roche· Source
Completed
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580· Phase 2· Boehringer Ingelheim· Source
Terminated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316· Phase 2· Agenus Inc.· Source
Terminated
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
NCT05494866· Phase 1· German Cancer Research Center· Source
Completed
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy
2022-500652-37-00· Phase 2· Agenus Inc.· Source
Completed
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· Phase 3· Bayer AG· Source

Showing 50 of 137.

Registry name variants (64)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Universitaetsklinikum Heidelberg AöR
Heidelberg, 69120
341 trials
Universitätsklinikum Heidelberg
Heidelberg, D-69126
46 trials
Universitaetsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg 69120
32 trials
University Hospital Heidelberg
Heidelberg, 69120
29 trials
Heidelberg University Hospital AöR
Heidelberg, 69120
20 trials
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, 69120
9 trials
Heidelberg University Hospital
Heidelberg, Baden-Wurttemberg 69120
7 trials
Heidelberg University Hospital, Department of Gynecology and Obstetrics
Heidelberg, 69120
2 trials
- NCT07106294Hyperspectral Imaging for Prediction of Preeclampsia
  Contact: Dr. med. Anna Scholz
- NCT06912477Endothelial Dysfunction for Prognosis In Patients With preeClampSia
  Contact: Dr. med. Anna Scholz
Heidelberg University Hospital - GMMG Study Group
Heidelberg, 69120
2 trials
- NCT07388147Exercise Therapy for Multiple Myeloma Patients
  Contact: Dapunt
- NCT07026799Feasibility, Safety and Effectivity of an Exercise Intervention for Newly Diagnosed Multiple Myeloma Patients During Induction Therapy
Universitaetsklinikum Heidelberg - Zentrum für Innere Medizin
Heidelberg, 69120
2 trials
- NCT05667493An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- NCT04136171CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
University Hospital of Heidelberg
Heidelberg, Baden-Wurttemberg 69120
2 trials
- NCT05774431Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
- NCT06128317Myocardial Infarction Registry
  Contact: Mustafa Yildirim, MD
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital
Heidelberg, 69126
1 trial
- NCT05464238Training in HFpEF-PH
  Contact: Ekkehard Grünig, MD
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital Heidelberg
Heidelberg, 69126
1 trial
- NCT05339087Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Department III of Internal Medicine, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg 69115
1 trial
- NCT04359238activeDCM - Interventional Clinical Trial of Individualized Activity and Exercise Programs to Improve Outcome in Dilated Cardiomyopathy Guided by Longitudinal Biosensing With Apple Watch
Department of Neurology, Heidelberg University Hospital
Heidelberg, 69120
1 trial
- NCT07299994Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
  Contact: Jan Purrucker, Prof. Dr.
Department of Neurology, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT05525325Mode of Sedation During Endovascular Treatment of Vertebrobasilar Stroke
  Contact: Silvia Schönenberger, Dr.
National Center for Tumour Diseases, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT04758325The Sarcoma Biology and Outcome Project
  Contact: Editha Gnutzmann, M.A.
Thoraxklinik Heidelberg gGmbH - Universitaetsklinikum Heidelberg, ThoraxKliPS
Heidelberg, 69126
1 trial
- NCT05595642A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Universitaetsklinikum Heidelberg
Mannheim, Baden-Wurttemberg 68169
1 trial
- NCT02467270Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
Universitaetsklinikum Heidelberg /ID# 272329
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Universitaetsklinikum Heidelberg /ID# 274164
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT06916507Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
Universitaetsklinikum Heidelberg /ID# 275906
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT06764706Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Universitaetsklinikum Heidelberg /ID# 278134
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Universitaetsklinikum Heidelberg (UKHD)
Heidelberg, 69126
1 trial
- NCT07392450A Study of TAK-755 in Adults With Acute Ischemic Stroke
  Contact: Jan Purrucker (principal investigator)
Universitaetsklinikum Heidelberg (UKHD) - Hautklinik
Heidelberg, 69120
1 trial
- NCT06112314IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  Contact: Prof. Jessica Hassel, MD
Universitaetsklinikum Heidelberg (UKHD) - Nationales Centrum fuer Tumorerkrankungen Heidelberg (NCT)
Heidelberg
1 trial
- NCT05948475Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
UniversitätsKlinikum Heidelberg
Mannheim, 68167
1 trial
- NCT03603184Atezolizumab Trial in Endometrial Cancer - AtTEnd
Universitätsklinikum Heidelberg - Children
Heidelberg, Baden-Württenberg 69120
1 trial
- NCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
  Contact: Maria Luisa Möller-Winheim
UNIVERSITÄTSKLINIKUM HEIDELBERG - Innere Medizin V
Heidelberg, 69120
1 trial
- NCT06284122Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Universitätsklinikum Heidelberg; Medizinische Universitätsklinik Heidelberg, Innere Medizin IV
Heidelberg, 69120
1 trial
- NCT07549607Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
  Contact: Theresa Wenz, Dr.
Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  Contact: Immatics US, Inc.
Universitätsklinikum Heidelberg, Thoraxklinik Heidelberg gGmbH
Heidelberg, 69126
1 trial
- NCT05281406Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
  Contact: Farastuk Bozorgmehr, Dr.
Universitätsklinikum Heidelberg (University of Heidelberg, Dept of Urology)
Heidelberg, 69120
1 trial
- NCT02766543Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer
Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin, Sektion für Neuropädiatrie und Stoffwechselmedizin
Heidelberg, 69120
1 trial
- NCT05554835Global Registry and Natural History Study for Mitochondrial Disorders
  Contact: Georg F. Hoffmann, Prof. Dr.
University Hospital Heidelberg, Department of Cardiology, Angiology and Respiratory Medicine
Heidelberg
1 trial
- NCT06075823Edge-to-edge Mitral Valve Repair in ATTR-CM
  Contact: Mathias Konstandin, MD
University Hospital Heidelberg, Department of Pediatric Hematology, Oncology and Immunology
Heidelberg, 69120
1 trial
- NCT04201210A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
  Contact: Johann Greil, MD
University Hospital Heidelberg, Department of Radiation Oncology
Heidelberg
1 trial
- NCT04141709Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer
University Hospital Heidelberg, Department of RadioOncology
Heidelberg, Baden-Wurttemberg 69120
1 trial
- NCT04946357Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions
University Hospital Heidelberg, Internal Medicine V
Heidelberg, 69120
1 trial
- NCT05662904Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
  Contact: Tim Sauer, Dr. med.
University Hospital of Heidelberg, Department of Radiation Oncology
Heidelberg, 69120
1 trial
- NCT03297788Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases
University Hospital of Heidelberg, Dep. of Radiation Oncology
Heidelberg
1 trial
- NCT05114213MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
Department of Cardiology, Heidelberg University Hospital
Heidelberg, 69120
Thoraxklinik Heidelberg gGmbH, Universitätsklinikum Heidelberg
Heidelberg, 69126
Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik
Heidelberg, DE 69120
Universitaetsklinikum Heidelberg /ID# 269438
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg /ID# 275598
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg, NCT-Dermatoonkologie
Heidelberg, 69120
Universitaetsklinikum Heidelberg / Neurologie
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg (Site 0401)
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg (Site 0531)
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg (Site 0805)
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg (Site 1100)
Heidelberg, Baden-Wurttemberg 69120
Universitaetsklinikum Heidelberg, Zentrum fuer Kinder und Jugendmedizin
Heidelberg, 69120
Universitätsklinikum Heidelberg - Angelika Lautenschläger - Kinderklinik
Heidelberg, 69120
Universitätsklinikum Heidelberg AöR
Heidelberg
Universitätsklinikum Heidelberg - Pädiatrisches Klinisch-Pharmakologisches Studienzentrum (paedKliPS)
Heidelberg, 69120
Universitätsklinikum Heidelberg, RadioOnkologie & Strahlentherapie
Heidelberg
Universitätsklinikum Heidelberg - Thoraxklinik Heidelberg
Heidelberg
Universitätsklinikum Heidelberg - Zentrum für Innere Medizin, Abteilung Klinische Pharmakologie und Pharmakoepidemologie
Heidelberg, Baden-Wurttemberg 69120
Universitätsklinikum Heidelberg, Zentrum für Kinder- und Jugendmedizin
Heidelberg, 69120
University Hospital Heidelberg, Department V, Hematology, Oncology and Rheumatology
Heidelberg, 69120
University Hospital Heidelberg, Im Neuenheimer Feld 430 (Site 276608)
Heidelberg, 69120
University Hospital Heidelberg /Universitätsklinikum Heidelberg
Heidelberg, 69120
Universkitatsklinikum Heidelberg - University Hospital Heidelberg
Heidelberg, 69126

Conditions

Diseases this institution publishes on or runs trials for.

Stroke150 works · 28 trials
Lung cancer140 works · 24 trials
Heart failure120 works · 25 trials
Sarcoma72 works · 17 trials
Liver and biliary tract cancer72 works · 11 trials
Glioblastoma71 works · 16 trials
Colorectal cancer69 works · 15 trials
Melanoma68 works · 41 trials
Multiple myeloma62 works · 42 trials
Atrial fibrillation56 works · 9 trials
Prostate cancer55 works · 17 trials
Pancreatic cancer54 works · 19 trials
Acute myeloid leukaemia42 works · 19 trials
Tuberculosis37 works · 1 trial
Amyloidosis36 works · 20 trials
Spinal cord injury35 works · 0 trials
Ovarian cancer28 works · 10 trials
COPD27 works · 1 trial
Meningioma20 works · 2 trials
Pulmonary arterial hypertension19 works · 5 trials
Head and neck cancer18 works · 10 trials
Cystic fibrosis15 works · 3 trials
Dilated cardiomyopathy15 works · 4 trials
Systemic sclerosis (scleroderma)15 works · 4 trials
Brain aneurysm14 works · 2 trials
Myocarditis14 works · 2 trials
Aortic aneurysm14 works · 4 trials
Childhood cancers11 works · 56 trials
Cerebral palsy11 works · 0 trials
Long COVID and ME/CFS10 works · 2 trials

Institution data: ROR 013czdx64 (CC0-1.0)Updated 12 Nov 2026

Report an error